tbuckley/cabot-search huggingface dataset:
AB0669 The Importance of Serum Visfatin Levels in Behcet's Disease Patients
Authors: M.E. Enecik, Z. Ozbalkan, G. Keskin, Y. Karaaslan
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> It9s a known fact that serum levels of the tumor necrosis factor Alfa (TNF-α) interleucin-6 (IL-6) and other proinflammatory cytokines which are released from the adipose tissue are increased in Behcet9s disease (BD). In BD adipose tissue is not a passive energy depot, it is an active endocrine organ and releases adipositokines. Visfatine is one of them. Visfatin is related to TNF-α and IL-6, IL-1 beta, co-stimulators like CD40, CD54, CD 80 and endothelial ICAM-1 and ICAM-2. We aimed to search the relation among levels of serum visfatin in BD activity. <h3>Methods</h3> 60BD patients (30 in active state and 30 in remission) who were diagnosed according to The Criteria of Working Group on International BD and 20 healthy subjects as controls were involeved in to the study. Serum visfatin levels were compared in between three groups. <h3>Results</h3> Visfatin levels were significantly higher in both group of patients compared to the healthy control group (both p&lt;0,001). Serum visfatin levels in active state patients were higher than those in inactive state (p&lt;0.001). The same way in all cases statistically significant correlation between visfatin and CRP (p&lt;0.001) and visfatin and ESR (p&lt;0.01). According to the symptoms of the patients in the active state, patients with genital aphtous ulcers had higher serum visfatin levels than the active patients without genital aphthous ulcers (p&lt;0,001). <h3>Conclusions</h3> Serum visfatin levels in BD patients with active and inactive states are higher than the healthy control group. That could be concluded as visfatin as a proinflammatory cytokines have a role in chronic inflammatory reactions and sustains the cellular expression of the inflammatory cytokines in BD. <h3>References</h3> Samara A, Clin Endocrinol (Oxf). 2008;29. Moschen AR, J Immunol. 2007;178:1748-1758. Yazici H, Curr Opin Rheumatol. 2001; 13:18-22. Sahin M, Ann Clin Lab Sci. 2006; 36:449-454. Moschen AR, J Immunol. 2007;178:1748-1758. 6- Samara AClin Endocrinol (Oxf). 2008;29. <h3>Disclosure of Interest</h3> None declared
Current prevalence of multidrug-resistant organisms in long-term care facilities in the Rhine-Main district, Germany, 2013
Authors: M Hogardt, P Proba, D Mischler, C Cuny, V A Kempf, U Heudorf
Journal: Eurosurveillance (2015)

Multidrug-resistant organisms (MDRO) and in particular multidrug-resistant Gram-negative organisms (MRGN) are an increasing problem in hospital care. However, data on the current prevalence of MDRO in long-term care facilities (LTCFs) are rare. To assess carriage rates of MDRO in LTCF residents in the German Rhine-Main region, we performed a point prevalence survey in 2013. Swabs from nose, throat and perineum were analysed for meticillin-resistant Staphylococcus aureus (MRSA), perianal swabs were analysed for extended-spectrum beta-lactamase (ESBL)-producing organisms, MRGN and vancomycin-resistant enterococci (VRE). In 26 LTCFs, 690 residents were enrolled for analysis of MRSA colonisation and 455 for analysis of rectal carriage of ESBL/MRGN and VRE. Prevalences for MRSA, ESBL/MRGN and VRE were 6.5%, 17.8%, and 0.4%, respectively. MRSA carriage was significantly associated with MRSA history, the presence of urinary catheters, percutaneous endoscopic gastrostomy tubes and previous antibiotic therapy, whereas ESBL/MRGN carriage was exclusively associated with urinary catheters. In conclusion, this study revealed no increase in MRSA prevalence in LTCFs since 2007. In contrast, the rate of ESBL/MRGN carriage in German LTCFs was remarkably high. In nearly all positive residents, MDRO carriage had not been known before, indicating a lack of screening efforts and/or a lack of information on hospital discharge.
Management of a new pregnancy in a woman with chronic hypertension
Authors: Pippa Oakeshott, Lucy C Chappell
Journal: BMJ (2016)

#### What you need to know A 28 year old woman attends surgery saying that she is six weeks pregnant with her second baby and would like to be referred to the midwives. She says that she had a problem with high blood pressure in her previous pregnancy three years ago and has been taking nifedipine and ramipril since then, as she continued to have high blood pressure when she tried to stop taking her tablets. She wonders if she should now stop these tablets and whether they are safe for her baby. ### Ask about
Treatment Outcomes and Prognostic Factors for Patients with Brain Metastases from Breast Cancer: a Multicenter Cohort Analysis
Authors: N. Masuda, N. Niikura, N. Hayashi, S. Takashima, R. Nakamura, K. Watanabe, C. Kanbayashi, M. Ishida, Y. Hozumi, M. Tsuneizumi, N. Kondo, Y. Naito, Y. Honda, A. Matsui, T. Fujisawa, R. Oshitanai, H. Yasojima, Y. Tokuda, S. Saji, H. Iwata
Journal: Annals of Oncology (2014)
Research directions in child psychiatry
Authors: I Philips
Journal: American Journal of Psychiatry (1980)

Current research in child psychiatry emphasizes the understanding of biological mechanisms of behavior and its aberrations but neglects the transactional relationships in interpersonal phenomena. This situation may led to an unwarranted enthusiasm for biological forms of treatment. The author calls attention to the importance of biopsychosocial elements of behavior in the understanding of growth and development. He discusses research directions to incorporate all elements of the behavioral sciences in the study of child behavior.
Interaction of Target Oxygen Saturation, Bronchopulmonary Dysplasia, and Pulmonary Hypertension in Small for Gestational Age Preterm Neonates
Authors: Satyan Lakshminrusimha, Veena Manja, Robin H. Steinhorn
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Scottish NHS Plan promises speedier treatment
Authors: Bryan Christie
Journal: BMJ (2001)

Every patient in Scotland has been given a guarantee that, from 2003, they will wait no longer than nine months for NHS hospital treatment. The pledge, which cuts the present maximum waiting time limit by three months, is contained in the Scottish NHS Plan, published last month. The plan contains additional commitments to speed up the diagnosis and treatment of conditions such as cancer and heart disease.

Women with breast cancer who need urgent attention will be treated within a month from October …
Morphology of a “Noninfectious” Sarcoma Virus
Authors: William T. Hall, Adi F. Gazdary, Barbara A. Hobbs, Harish C. Chopra
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Morphology of a “Noninfectious” Sarcoma Virus Get access William T. Hall, William T. Hall Search for other works by this author on: Oxford Academic PubMed Google Scholar Adi F. Gazdary, Adi F. Gazdary Search for other works by this author on: Oxford Academic PubMed Google Scholar Barbara A. Hobbs, Barbara A. Hobbs Search for other works by this author on: Oxford Academic PubMed Google Scholar Harish C. Chopra Harish C. Chopra Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 4, April 1974, Pages 1337–1343, https://doi.org/10.1093/jnci/52.4.1337 Published: 01 April 1974 Article history Received: 13 November 1973 Accepted: 16 January 1974 Published: 01 April 1974
AB0925 Prerequisites for the Organization of Gout School in Yakutsk
Authors: M.N. Petrova
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Gout is considered a metabolic disease and ranked among the diseases connected with obesity, such as an arterial hypertension (AH), coronary artery disease (CAD), stroke, and type 2 diabetes mellitus (WHO, 2000). It has been proven that intake of a considerable quantity of meat products is predictor of acute gouty arthritis. For this reason there is great interest in studying the prevalence of gout among inhabitants of the Republic of Sakha (Yakutia) where a lipid-protein diet prevails. Official data on gout in Yakutia are absent. <h3>Objectives</h3> A research project has been initiated to determine the incidence and characteristics of gout in Yakutia from 2007-2012. Patients hospitalized in the department of rheumatology of Yakut City Hospital with gouty arthritis were studied. <h3>Methods</h3> Patients are being studied by means of a questionnaire developed by the Institute of Rheumatology (Moscow). <h3>Results</h3> 44 patients were registered. Median age of the subjects is 56 years [35-76]. Secondary forms of gout and relapses of disease are common. Accompanying pathology includes: AH in 22 patients, CAD in 7 patient, NIDDM in 4 patients, chronic renal insufficiency in 1 patient, and cardiovascular accidents in 3 patients. Nephrolithiasis in 9 patients only in patients with AH. Metabolic syndrome features in patients with gout: obesity-50%; AH (≥130/85 mm.Hg)-92%; TG (≥1,7mmol/l) - 71%; Glucose (&gt;6,1 mmol/l) – 12,5%. <h3>Conclusions</h3> Thus, we observed gout in both elderly patients, predominately men, and some young men, among them there were repeated hospitalizations and multiple risk factors. Results will be used for characterization of the incidence and diagnostic features of gout in the Republic of Sakha (Yakutia) with the goal of standardizing guidelines for diagnosis and treatment of gout. <h3>References</h3> Nasonova V.A., Barskova V.G. Early diagnosis and treatment of gout - scientifically justified demand to improve of employment and life prognosis of patients. Scientific and Practical Rheumatology 2004;1:5-7. <h3>Acknowledgements</h3> Institute of Rheumatology (Moscow), Yakut City Hospital, NEFU (Yakutsk). <h3>Disclosure of Interest</h3> None declared
PTU-142 The ongoing use of diagnostic barium swallow for dysphagia should be abandoned
Authors: E Hardy, R Dhingsa, S Parsons
Journal: Gut (2015)

<h3>Introduction</h3> Whereas gastroenterology and upper GI surgery have largely abandoned barium swallow for diagnostic purposes, ENT surgeons still request barium swallows to investigate patients with “high dysphagia”. We analysed these from a cost effective point of view. <h3>Method</h3> All Barium Swallows requested by ENT surgeons as the primary investigation of “dysphagia” over a two year period were retrospectively reviewed. Requests were filtered to only include ENT requests with dysphagia as the clinical indication. Whether these patients went on to OGD was also determined. <h3>Results</h3> 246 Barium Swallows were completed between January 2013 to December 2014. 51% (126) were reported as normal, and the most common diagnoses were gastro-oesophageal reflux (44), hiatus hernia (45) and oesophageal dysmotility (31). Pharyngeal pouch was diagnosed in nine patients. No patients had hypopharyngeal tumours. Suspicion of oesophago-gastric malignancy was reported in 16 patients with four patients subsequently confirmed to have oesophageal cancer on OGD. The average wait in these patients from request of Barium Swallow to histological diagnosis was 37 days, breaching the 31 day target. 72 Patients (26%) went on to have an OGD, and this provided additional diagnostic information in 56% (40) including Barrett’s Oesophagus in 4%. If all patients had been initially investigated with OGD, instead of Barium Swallow, a net saving of £1,400 would have been made. <h3>Conclusion</h3> Diagnostic barium swallow for dysphagia delays diagnosis of oesophageal cancer and overall is more expensive than the preferred definitive OGD. <h3>Disclosure of interest</h3> None Declared.
AB1251-HPR Young Adults Preferences on Content and Structure of Patient Education in Rheumatic Diseases
Authors: B. Jakobsen, I.R. Nilssen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Inflammatory rheumatic diseases are characterized by pain, stiffness, fatigue, reduced functioning and reduced wellbeing, and can consequently affect patients in their everyday life. Young people with rheumatic disease have to deal with the normal challenges that comes with their age, such as starting an education, adjusting to working life, relating to friends, family and partners, and handling physical and emotional changes; in addition to coping with their rheumatic disease. These patients may therefore have other preferences to patient education then other patient groups. <h3>Objectives</h3> The objective of this quality project was to gain insight in young patient9s preferences of perceived educational needs before planning a patient education program based on our findings. <h3>Methods</h3> The participants (N=20) were patients with an established rheumatic disease aged 18-25 years visiting the rheumatology outpatient clinic at St. Olavs Hospital from June to December 2014. All patients were asked to answer a questionnaire regarding preferences on content and structure of a patient education program. The questions were: Are you interested in participating in a patient education program for young adults? What time of the day and duration of the program would you prefer? Which topics would you like to have in a program? Why would you participate in a patient education program? All questions had boxes to tick, and on the question on topics, the patients could also write other topics then the ones listed. Patients were able to tick more than one box on each topic. <h3>Results</h3> 95% of the patients wanted to participate in a patient education program for young adults. 42% preferred an organization with two meetings in the afternoon lasting for 4 hours each. The patients wanted the topics to be: Diet (60%), to live with a chronic rheumatic disease (55%), social benefit rights (50%), physical exercise (45%), hearing other young adults experiences (40%), pregnancy (35%), disease information (35%), adaptive equipment9s (25%), sex and intimate relationships (20%) and information about patient organizations (10%). 55% answered that the most important for them if they were to participate in an education program would be learning more about how to live with their rheumatic disease, 45% said that meeting others with a rheumatic disease was important and only 20% meant that learning more about the rheumatic disease itself was most important. <h3>Conclusions</h3> To develop a patient education program for young adults, it is important to know the patients preferences. From this questionnaire we learned that patients were interested in an educational program targeted specifically at young adults. Their main focus is to learn more about how to live with their disease in a best possible way, and meeting others with the same disease to learn from each other. <h3>Disclosure of Interest</h3> None declared
Comparison of fluorescent polarization immunoassay and radioimmunoassay in measuring cortisol levels in prepubertal depressed children
Authors: R A Weller, S Yaylayan, E B Weller, M A Fristad
Journal: American Journal of Psychiatry (1992)

Cortisol levels of 21 hospitalized prepubertal depressed children given the dexamethasone suppression test (DST) were measured by radioimmunoassay and by fluorescent polarization immunoassay, a new assay method. Correlation analyses demonstrated a highly significant linear relationship between the two methods of measuring cortisol. Thus, it may be possible to use fluorescent polarization immunoassay to measure cortisol levels in children undergoing the DST.
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA–Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Authors: Christian Kurzeder, Isabel Bover, Frederik Marmé, Joern Rau, Patricia Pautier, Nicoletta Colombo, Domenica Lorusso, Petronella Ottevanger, Maria Bjurberg, Christian Marth, Pilar Barretina-Ginesta, Ignace Vergote, Anne Floquet, Josep M. del Campo, Sven Mahner, Lydie Bastière-Truchot, Nicolas Martin, Mikkel Z. Oestergaard, Astrid Kiermaier, Carmen Schade-Brittinger, Sandra Polleis, Andreas du Bois, Antonio Gonzalez-Martin
Journal: Journal of Clinical Oncology (2016)

Purpose The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the primary efficacy analysis. Patients and Methods Eligible patients had ovarian carcinoma that progressed during or within 6 months of completing four or more platinum cycles, centrally tested low tumor HER3 mRNA expression (concentration ratio ≤ 2.81 by quantitative reverse transcriptase polymerase chain reaction on cobas z480 [Roche Molecular Diagnostics, Pleasanton, CA]), and no more than two prior lines of chemotherapy. After investigators’ selection of the chemotherapy backbone (single-agent topotecan, weekly paclitaxel, or gemcitabine), patients were randomly assigned to also receive either placebo or pertuzumab (840-mg loading dose followed by 420 mg every 3 weeks). Stratification factors were selected chemotherapy, prior antiangiogenic therapy, and platinum-free interval. The primary end point was independent review committee–assessed progression-free survival (PFS). Additional end points included overall survival, investigator-assessed PFS, objective response rate, safety, patient-reported outcomes, and translational research. Results Overall, 156 patients were randomly assigned. Adding pertuzumab to chemotherapy did not significantly improve independent review committee–assessed PFS for the primary analysis (stratified hazard ratio, 0.74; 95% CI, 0.50 to 1.11; P = .14; median PFS, 4.3 months for pertuzumab plus chemotherapy v 2.6 months for placebo plus chemotherapy). Sensitivity analyses and secondary efficacy end point results were consistent with the primary analysis. The effect on PFS favoring pertuzumab was more pronounced in the gemcitabine and paclitaxel cohorts. No new safety signals were seen. Conclusion Although the primary objective was not met, subgroup analyses showed trends in PFS favoring pertuzumab in the gemcitabine and paclitaxel cohorts, meriting further exploration of pertuzumab in ovarian cancer.
Invasive FFR and Noninvasive CFR in the Evaluation of Ischemia
Authors: Nils P. Johnson, K. Lance Gould, Marcelo F. Di Carli, Viviany R. Taqueti
Journal: Journal of the American College of Cardiology (2016)

This review provides an integrative and forward-looking perspective on the gamut of coronary physiology for the diagnosis and management of atherosclerosis. Because clinical events serve as the ultimate gold standard, the future of all diagnostic tests, including invasive fractional flow reserve and noninvasive coronary flow reserve, depends on their ability to improve patient outcomes. Given the prominent role of acute coronary syndromes and invasive procedures in cardiology, we practically consider 2 broad categories of patients with coronary disease: acute and stable. For patients with acute coronary disease, coronary physiology may potentially refine treatment of the culprit lesion. For both patients with stable and acute nonculprit disease, reducing hard endpoints with revascularization potentially occurs at the severe end of the focal physiological spectrum, an area under-represented in existing trials. Nonepicardial disease and diffuse atherosclerosis remain underexplored aspects of coronary physiology for testing of novel treatments.
Biochemical Investigations on Hepatic Carcinogenesis&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: Elizabeth C. Miller, James A. Miller
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Biochemical Investigations on Hepatic Carcinogenesis, Get access Elizabeth C. Miller, Elizabeth C. Miller McArdle Memorial Laboratory for Cancer Research, Medical School, University of Wisconsin, Madison, Wis Search for other works by this author on: Oxford Academic PubMed Google Scholar James A. Miller James A. Miller McArdle Memorial Laboratory for Cancer Research, Medical School, University of Wisconsin, Madison, Wis Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1571–1590, https://doi.org/10.1093/jnci/15.Supplement_5.1571 Published: 01 April 1955
Second cancers after pediatric Hodgkin's disease.
Authors: S Bhatia, A T Meadows, L L Robison
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.7.2570 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9667281 Second cancers after pediatric Hodgkin's disease. S BhatiaxS BhatiaSearch for articles by this author , A T MeadowsxA T MeadowsSearch for articles by this author , L L RobisonxL L RobisonSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.7.2570 First Page PDF © 1998 by American Society of Clinical Oncology
Comparing Clinicopathologic and Radiographic Findings Between TT-UMP, Classical, and Non-Encapsulated Follicular Variants of Papillary Thyroid Carcinomas
Authors: Husniye Baser, Oya Topaloglu, Abbas Ali Tam, Afra Alkan, Aydan Kilicarslan, Reyhan Ersoy, Bekir Cakir
Journal: Endocrine Pathology (2016)
Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3–specific receptor beta-chain–null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor
Authors: Clare L. Scott, Lorraine Robb, Bette Papaevangeliou, Rachel Mansfield, Nicos A. Nicola, C. Glenn Begley
Journal: Blood (2000)
Metabolic regulation of immune responses: therapeutic opportunities
Authors: Nadine Assmann, David K. Finlay
Journal: Journal of Clinical Investigation (2016)

Immune cell metabolism is dynamically regulated in parallel with the substantial changes in cellular function that accompany immune cell activation. While these changes in metabolism are important for facilitating the increased energetic and biosynthetic demands of activated cells, immune cell metabolism also has direct roles in controlling the functions of immune cells and shaping the immune response. A theme is emerging wherein nutrients, metabolic enzymes, and metabolites can act as an extension of the established immune signal transduction pathways, thereby adding an extra layer of complexity to the regulation of immunity. This Review will outline the metabolic configurations adopted by different immune cell subsets, describe the emerging roles for metabolic enzymes and metabolites in the control of immune cell function, and discuss the therapeutic implications of this emerging immune regulatory axis.